373 related articles for article (PubMed ID: 26198913)
1. Safety and efficacy of reduced fingolimod dosage treatment.
Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
3. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
7. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
[TBL] [Abstract][Full Text] [Related]
10. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
Tanaka M; Park K; Tanaka K
Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
[No Abstract] [Full Text] [Related]
11. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod for multiple sclerosis.
Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
15. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N; Kim E
Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
[TBL] [Abstract][Full Text] [Related]
17. Management of fingolimod in clinical practice.
Thomas K; Ziemssen T
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
[TBL] [Abstract][Full Text] [Related]
18. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
[TBL] [Abstract][Full Text] [Related]
19. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S
Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
Tanasescu R; Constantinescu CS
Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]